临床合理用药杂志
臨床閤理用藥雜誌
림상합리용약잡지
CHINESE JOURNAL OF CLINICAL RATIONAL DRUG USE
2015年
15期
13-15
,共3页
乙型肝炎,慢性%凯因益生伴侣颗粒%干扰素类%前瞻性研究%治疗结果
乙型肝炎,慢性%凱因益生伴侶顆粒%榦擾素類%前瞻性研究%治療結果
을형간염,만성%개인익생반려과립%간우소류%전첨성연구%치료결과
Hepatitis B,chronic%Kain prebiotic partner particles%Interferons%Prospective studies%Treatment outcome
目的:探讨凯因益生伴侣颗粒联合干扰素α-2b治疗慢性乙型肝炎的临床疗效。方法选取2012年2月—2013年2月在邯郸市传染病医院接受治疗的慢性乙型肝炎患者120例,随机分为干预组和对照组,各60例。对照组在基础保肝、降酶支持对症治疗的基础上给予重组人α-2b干扰素治疗,干预组在对照组基础上给予凯因益生伴侣颗粒治疗,检测并比较两组患者的肝功能指标、血清HBsAg水平、血清HBV-DNA水平、血清HBeAg/HBeAb转换率。结果治疗12周后干预组的谷氨酸氨基转移酶( ALT)、天冬氨酸氨基转移酶( AST)、总胆红素( TBiL)低于对照组,差异有统计学意义( P<0.05)。治疗后4周、8周、12周干预组血清HBsAg水平、血清HBV-DNA水平低于对照组,差异有统计学意义( P<0.05)。治疗后两组不同血清HBsAg水平的患者血清HBeAg/HBeAb转换率比较,差异无统计学意义( P>0.05);治疗后12周,干预组血清HBeAg/HBeAb转换率高于对照组,差异有统计学意义(P<0.05)。结论凯因益生伴侣颗粒联合干扰素是慢性乙型肝炎抗病毒治疗的有效药物,与单纯干扰素用药相比,具有明显的改善患者肝功能、降低血清HBsAg水平及血清DNA水平、降低血清HBeAg/HBeAb转换率的效果。
目的:探討凱因益生伴侶顆粒聯閤榦擾素α-2b治療慢性乙型肝炎的臨床療效。方法選取2012年2月—2013年2月在邯鄲市傳染病醫院接受治療的慢性乙型肝炎患者120例,隨機分為榦預組和對照組,各60例。對照組在基礎保肝、降酶支持對癥治療的基礎上給予重組人α-2b榦擾素治療,榦預組在對照組基礎上給予凱因益生伴侶顆粒治療,檢測併比較兩組患者的肝功能指標、血清HBsAg水平、血清HBV-DNA水平、血清HBeAg/HBeAb轉換率。結果治療12週後榦預組的穀氨痠氨基轉移酶( ALT)、天鼕氨痠氨基轉移酶( AST)、總膽紅素( TBiL)低于對照組,差異有統計學意義( P<0.05)。治療後4週、8週、12週榦預組血清HBsAg水平、血清HBV-DNA水平低于對照組,差異有統計學意義( P<0.05)。治療後兩組不同血清HBsAg水平的患者血清HBeAg/HBeAb轉換率比較,差異無統計學意義( P>0.05);治療後12週,榦預組血清HBeAg/HBeAb轉換率高于對照組,差異有統計學意義(P<0.05)。結論凱因益生伴侶顆粒聯閤榦擾素是慢性乙型肝炎抗病毒治療的有效藥物,與單純榦擾素用藥相比,具有明顯的改善患者肝功能、降低血清HBsAg水平及血清DNA水平、降低血清HBeAg/HBeAb轉換率的效果。
목적:탐토개인익생반려과립연합간우소α-2b치료만성을형간염적림상료효。방법선취2012년2월—2013년2월재함단시전염병의원접수치료적만성을형간염환자120례,수궤분위간예조화대조조,각60례。대조조재기출보간、강매지지대증치료적기출상급여중조인α-2b간우소치료,간예조재대조조기출상급여개인익생반려과립치료,검측병비교량조환자적간공능지표、혈청HBsAg수평、혈청HBV-DNA수평、혈청HBeAg/HBeAb전환솔。결과치료12주후간예조적곡안산안기전이매( ALT)、천동안산안기전이매( AST)、총담홍소( TBiL)저우대조조,차이유통계학의의( P<0.05)。치료후4주、8주、12주간예조혈청HBsAg수평、혈청HBV-DNA수평저우대조조,차이유통계학의의( P<0.05)。치료후량조불동혈청HBsAg수평적환자혈청HBeAg/HBeAb전환솔비교,차이무통계학의의( P>0.05);치료후12주,간예조혈청HBeAg/HBeAb전환솔고우대조조,차이유통계학의의(P<0.05)。결론개인익생반려과립연합간우소시만성을형간염항병독치료적유효약물,여단순간우소용약상비,구유명현적개선환자간공능、강저혈청HBsAg수평급혈청DNA수평、강저혈청HBeAg/HBeAb전환솔적효과。
Objective To study the clinical effect of Kain partner particles combined with interferon in the treatment of chronic hepatitis B. Methods In Infectious Disease Hospital of Handan from February 2012 to 2013,120 patients with chronic hepatitis B were selected and randomly devided into treatment group and control group,60 cases in each group. Control group were treated with human recombinant alpha-2b interferon on the basis of protect liver,fall enzyme support symptomatic treatment,treatment group were treated with Kain prebiotic partner particles on the basis of control group. Liver function,serum HBsAg level,serum HBV-DNA level,serum HBeAg/HBeAb conversion rate between the two groups were compared. Results 12 weeks after treatment,ALT,AST,TBiL of treatment group were lower than control group(P<0. 05);4,8,12 weeks after treatment serum HBsAg levels and serum HBV-DNA levels of the treatment group were lower than those of the control group(P<0. 05). After treatment,serum HBeAg / HBeAb conversion rate between two groups with different HBsAg levels showed no significant differences(P>0. 05);12 weeks after treatment,serum HBeAg / HBeAb conversion rate of treatment group was higher than than control group(P<0. 05). Conclusion Kain prebiotic partner particles combination with interferon are effective drugs in the treatment of chronic hepatitis B,liver function,serum HBsAg levels and serum DNA level,serum HBeAg/HBeAb conversion rate are better than that of simple interferon treatment.